From the *Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI; † Department of Radiation Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; ‡Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA; §Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Clin Nucl Med. 2016 Feb;41(2):106-17. doi: 10.1097/RLU.0000000000001036.
This practice parameter is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Such therapy requires close cooperation and communication between the physicians who are responsible for the clinical management of the patient and those who administer radiopharmaceutical therapy and manage the attendant side effects. Adherence to this practice parameter should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The goal of therapy with unsealed radiopharmaceutical sources is to provide either cure or effective palliation of disease while minimizing untoward side effects and complications.
本实践参数旨在指导经过适当培训和许可的医生使用未密封放射性药物源进行治疗。这种治疗需要负责患者临床管理的医生与进行放射性药物治疗和管理相关副作用的医生之间密切合作和沟通。遵守本实践参数应有助于最大限度地提高这些程序的有效性，保持安全条件，并确保遵守适用法规。使用未密封放射性药物源进行治疗的目的是在最小化不良副作用和并发症的同时，提供疾病的治愈或有效缓解。
